StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note published on Thursday morning. The brokerage issued a hold rating on the stock.
Separately, HC Wainwright restated a buy rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research note on Thursday, May 9th.
Read Our Latest Stock Analysis on Can-Fite BioPharma
Can-Fite BioPharma Stock Up 6.4 %
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Can-Fite BioPharma stock. Schechter Investment Advisors LLC purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned approximately 0.57% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission. 21.00% of the stock is currently owned by institutional investors.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Read More
- Five stocks we like better than Can-Fite BioPharma
- What is the Shanghai Stock Exchange Composite Index?
- Top 3 Defense Stocks That Should Be on Your Radar
- Industrial Products Stocks Investing
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.